Bristol Myers Squibb to Build $2.3B Drug Manufacturing Campus in Houston
On Monday, Bristol Myers Squibb revealed its intention to establish a $2.3 billion drug manufacturing facility in Houston, Texas, as part of a broader $40 billion investment in the U.S. over the next five years. The 600,000-square-foot site located at Generation Park will focus on producing a range of medications, including small molecules and biologics. The project is expected to create nearly 500 jobs and generate around 2,000 construction positions by 2030. CEO Christopher Boerner expressed strong faith in U.S. biopharmaceutical innovation, while Texas Governor Greg Abbott highlighted the potential for a $4.89 million grant. After assessing various locations, Bristol Myers chose Houston and increased its full-year revenue forecast to between $49 billion and $50 billion, fueled by drugs such as Eliquis, Camzyos, and Reblozyl.
Key facts
- Bristol Myers Squibb will build a $2.3 billion drug manufacturing campus in Houston, Texas.
- The campus will be located at Generation Park, a 4,300-acre site in Houston.
- The facility will be approximately 600,000 square feet and produce small molecules, biologics, and antibody-drug conjugates.
- The campus is expected to employ nearly 500 people and support about 2,000 construction workers through 2030.
- Bristol Myers is eligible for a $4.89 million grant from the Texas Enterprise Fund and incentives under the Jobs, Energy, Technology and Innovation program.
- The company raised its full-year revenue guidance to approximately $49 billion to $50 billion.
- Bristol Myers invested approximately $10 billion in research and development in 2025.
- Other drugmakers like Eli Lilly, Johnson & Johnson, Roche, and Pfizer are also expanding U.S. manufacturing.
Entities
Institutions
- Bristol Myers Squibb
- Texas Enterprise Fund
- Eli Lilly
- Johnson & Johnson
- Roche
- Pfizer
Locations
- Houston
- Texas
- United States
- Generation Park
Sources
- Quartz —